{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-036020","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2022-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.921631+00:00","generated_at":"2026-06-24T22:09:56.646673+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Allarity Therapeutics CEO Steve Carchedi and CFO Jens Knudsen resign; James Cullem interim CEO, Joan Brown interim CFO","bullets":["CEO Steve Carchedi resigned effective June 29, 2022; CFO Jens Knudsen resigned effective June 27, 2022, both to pursue other opportunities.","Board appointed James Cullem, current Chief Business Officer, as interim CEO; he continues as CBO.","Board appointed Joan Brown, current Director of Financial Reporting, as interim CFO; she continues as Director of Financial Reporting.","Permanent CEO and CFO expected to be named in H1 2023, per press release.","Co-founders Dr. Steen Knudsen (CSO) and Dr. Marie Foegh (CMO) remain in roles; Thomas Jensen becomes SVP of Investor Relations."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-036020","json":"https://secwatch.observer/filing/0001213900-22-036020.json","markdown":"https://secwatch.observer/filing/0001213900-22-036020.md","text":"https://secwatch.observer/filing/0001213900-22-036020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022036020/0001213900-22-036020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022036020/ea162285-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T22:09:56.646673+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"01aad30fbd","claim":"James Cullem was appointed as interim Chief Executive Officer at Allarity Therapeutics, Inc..","evidence_excerpt":"the Board of Directors of the Company (the “Board”) appointed James Cullem, the Company’s current Chief Business Officer, as the interim Chief Executive Officer of the Company effective as of June 29, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022036020/0001213900-22-036020-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"746eedc848","claim":"Steve Carchedi resigned as Chief Executive Officer at Allarity Therapeutics, Inc..","evidence_excerpt":"Effective as of June 29, 2022, Steve Carchedi resigned from all positions in Allarity Therapeutics, Inc. (the “Company”), and all positions of its subsidiaries, including his role of Chief Executive Officer and as a director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022036020/0001213900-22-036020-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"7b97e85420","claim":"Jens Knudsen resigned as Chief Financial Officer at Allarity Therapeutics, Inc..","evidence_excerpt":"Effective as of June 27, 2022, Jens Knudsen resigned from all positions in the Company, and all positions of its subsidiaries, including his role of Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022036020/0001213900-22-036020-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"a114aad9b8","claim":"Joan Brown was appointed as interim Chief Financial Officer at Allarity Therapeutics, Inc..","evidence_excerpt":"the Board appointed Joan Brown, the Company’s current Director of Financial Reporting, as the interim Chief Financial Officer of the Company effective as of June 29, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022036020/0001213900-22-036020-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}